You are here
Advertising: Regulatory decisions and announcements
Important decisions and announcements relating to advertisements of therapeutic goods will be published here. This includes certain compliance and enforcement actions, such as direction letters and public warning notices regarding non-compliant ads when required.
- Decisions to withdraw medicines advertising approval
- Notices of approved and permitted restricted representations
- Advertising directions notices
- TGA cracking down on non-compliant advertising of bioresonance and similar devices
$10 million penalty ordered against Peptide Clinics Pty Ltd for advertising breaches
23 July 2019 The Federal Court ordered that Peptide Clinics Australia (Peptide Clinics Pty Ltd) pay $10 million to the Commonwealth for breaches of the mandatory rules for advertising of medicines, including the ban on advertising prescription-only medicines to the public
TGA continues action against Peptide Clinics Australia for alleged advertising breaches
17 May 2019 The Federal Court has granted leave to the Secretary of the Department of Health to continue court proceedings against Peptide Clinics Australia following the company's liquidation in March this year.
TGA action against Peptide Clinics Pty Ltd for alleged advertising breaches
14 December 2018 This legal action follows an investigation by the Therapeutic Goods Administration
Public warning notices
Human placenta ingestion
19 Jan 2018 We are advising expectant mothers to be aware of the potential risks associated with placenta consumption
Resolution - Potential distribution of samples of therapeutic goods
27 Sep 2018 TGA has worked with Chemist Warehouse to ensure that none of the seat cushions to be placed at the NRL Grand Finals will contain therapeutic goods other than some approved sunscreen samples
Complaint outcomes and decisions pre July 2018
Before 1 July 2018, advertising complaints were handled under a different framework. For information about this framework and the publication of outcomes under this framework, see the Complaints Resolution Panel.